|
|
| | 3-Ethynylimidazo[1,2-b]pyridazine Basic information |
| Product Name: | 3-Ethynylimidazo[1,2-b]pyridazine | | Synonyms: | 3-Ethynylimidazo[1,2-b]pyridazine;IMidazo[1,2-b]pyridazine, 3-ethynyl-;Ponatinib Impurity 1;3-Ethynylimidazolo[1,2-b]pyridazine;3-Ethynylimidazo[1,2-b]pyridazine - [E11554];3-Alkynylimidazo[1,2-b]pyridazine;3-yneylimidazole[1,2-B]azine | | CAS: | 943320-61-4 | | MF: | C8H5N3 | | MW: | 143.15 | | EINECS: | | | Product Categories: | | | Mol File: | 943320-61-4.mol | ![3-Ethynylimidazo[1,2-b]pyridazine Structure](CAS2/GIF/943320-61-4.gif) |
| | 3-Ethynylimidazo[1,2-b]pyridazine Chemical Properties |
| density | 1.15±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | pka | 3.71±0.30(Predicted) | | form | solid | | color | White to grey | | InChI | InChI=1S/C8H5N3/c1-2-7-6-9-8-4-3-5-10-11(7)8/h1,3-6H | | InChIKey | VYOHSFQVMLAURO-UHFFFAOYSA-N | | SMILES | C12=NC=C(C#C)N1N=CC=C2 |
| | 3-Ethynylimidazo[1,2-b]pyridazine Usage And Synthesis |
| Uses | 3-Ethynylimidazo[1,2-b]pyridazine is used as an intermediate of Ponatinib, a BCR-ABL tyrosine kinase inhibitor anticancer drug used in the treatment of chronic myeloid leukaemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). | | Application | 3-Ethynylimidazo[1,2-b]pyridazine, a reactive heterocyclic building block, acts as a key intermediate for synthesizing antitumor drugs (e.g., ponatinib), designing bioactive derivatives, developing organic optoelectronic materials, and serving as an impurity reference standard for pharmaceutical quality control. |
| | 3-Ethynylimidazo[1,2-b]pyridazine Preparation Products And Raw materials |
|